Starpharma (ASX:SPL) has received an upfront payment of US$5.5 million (A$8.5 million) from Genentech, a member of the Roche Group, marking the formal commencement of their recently announced license agreement focused on developing dendrimer-drug conjugates for selected oncology targets.
Starpharma receives upfront payment from Genentech, launching oncology collaboration
October 23, 2025 Australian Biotech
Latest Video
New Stories
-
Queensland cardiac experts back a new plan to stop the second heart attack
September 18, 2026 - - Latest News -
We have one of Australia's answers to 'MFN' and people will die as a result
September 18, 2026 - - Latest News -
Is the fairest part of our medicines access system delivered overseas?
September 18, 2026 - - Latest News -
Mayne Pharma bets on an untapped corner of the menopause market
September 17, 2026 - - Latest News -
Genomic testing to reach more patients with hard to treat cancers
September 17, 2026 - - Latest News -
Eight women named finalists for 2026 Marie Krogh Young Women in Science Prize
September 17, 2026 - - Latest News -
'Your success makes you a target and take it as a compliment'
September 16, 2026 - - Latest News
